Your browser doesn't support javascript.
loading
Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
Fukudo, S; Matsueda, K; Haruma, K; Ida, M; Hayase, H; Akiho, H; Nakashima, Y; Hongo, M.
Affiliation
  • Fukudo S; Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Matsueda K; Sakura Life Clinic, Tokyo, Japan.
  • Haruma K; Department of Gastroenterology, Kawasaki Medical University, Kurashiki, Japan.
  • Ida M; Japan-Asia Planning & Administration, Medical & Development, Astellas Pharma Inc., Tokyo, Japan.
  • Hayase H; Japan-Asia Clinical Development 2, Development, Astellas Pharma Inc., Tokyo, Japan.
  • Akiho H; Japan-Asia Clinical Development 2, Development, Astellas Pharma Inc., Tokyo, Japan.
  • Nakashima Y; Japan-Asia Data Science, Development, Astellas Pharma Inc., Tokyo, Japan.
  • Hongo M; Kurokawa Hospital, Miyagi, Japan.
Article in En | MEDLINE | ID: mdl-28205278

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Serotonin Antagonists / Benzimidazoles / Irritable Bowel Syndrome / Diarrhea Type of study: Clinical_trials Limits: Adult / Female / Humans / Middle aged Language: En Journal: Neurogastroenterol Motil Journal subject: GASTROENTEROLOGIA / NEUROLOGIA Year: 2017 Document type: Article Affiliation country: Japan Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Serotonin Antagonists / Benzimidazoles / Irritable Bowel Syndrome / Diarrhea Type of study: Clinical_trials Limits: Adult / Female / Humans / Middle aged Language: En Journal: Neurogastroenterol Motil Journal subject: GASTROENTEROLOGIA / NEUROLOGIA Year: 2017 Document type: Article Affiliation country: Japan Country of publication: United kingdom